Europe’s leading entrepreneurs leads Series C Round in Sophia Genetics
scroll south
Sophia Genetics announces the closing of a $15 million Series C financing round led by Omega founder and Belgian billionaire Marc Coucke. With the support of Marc Coucke and Mike Lynch, Sophia Genetics is now backed by two of Europe’s leading entrepreneurs.
The venturelab alumnus Sophia Genetics was the best biotech startup in the TOP 100 now the team announced the closing of a new $15 million Series C financing round led by Omega founder and healthcare scion Marc Coucke. The funds will be used to continue Sophia Genetics' rapid market expansion and broaden its range of genomic tests.Witnessing a 400% growth rate this year alone, Sophia Genetics now supports more than 100 healthcare institutions across 20 countries. Its innovative analytics platform holds unique machine learning based algorithms and hosts the world’s largest clinical genomics community, placing Europe ahead of the US in precision medicine.
Leading this financing round, Omega founder and Belgian billionaire Marc Coucke explained, “Sophia Genetics stood out among an increasingly crowded field as it is so far ahead in fulfilling the promise of genomic testing, particularly in the fight against cancer. I have no doubt that the company will continue to thrive as more hospitals and labs adopt its cutting edge molecular diagnosis solutions, to the benefit of patients all over Europe.”
Marc Coucke founded Omega Pharma in 1987 and sold it to global healthcare supplier Perrigo in 2014 for more than $4.5 billion.
Sophia Genetics has previously received backing from Mike Lynch, founder of Invoke Capital. With both Coucke and Lynch as major investors, Sophia Genetics now counts support from two of Europe’s most successful life science and technology entrepreneurs in the last decade. Such recognition exemplifies Sophia Genetics’ success and the potential of its technology to change the healthcare industry by making precision medicine a reality.
Jurgi Camblong, CEO and co-founder of Sophia Genetics commented, “Sophia Genetics has experienced incredible growth over the past 18 months, driven by our superior analytical performance which allows hospitals to conduct genomics tests on cancers and genetic diseases. We have made the dream of precision medicine a reality for 25,000 patients so far, and more continue to benefit every day.”
